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Abstract
In addition to being involved in nutrient uptake, the epithelial mucosa constitute the ®rst line of
defense against microbial pathogens. A direct consequence of this physiological function is a very
complex network of immunological interactions that lead to a strong control of the mucosal
immune balance. The dysfunction of immunological tolerance is likely to be a cause of
in¯ammatory bowel disease (IBD), ulcerative colitis (UC) and Crohn's disease (CD). HLA-G is a
non-classical major histocompatibility complex (HLA) class I molecule, which is highly expressed
by human cytotrophoblast cells. These cells play a role in immune tolerance by protecting
trophoblasts from being killed by uterine NK cells. Because of the deregulation of immune system
activity in IBD, as well as the immunoregulatory role of HLA-G, we have analyzed the expression of
HLA-G in intestinal biopsies of patients with UC and CD. Our study shows that the differential
expression of HLA-G provides a potential way to distinguish between UC and CD. Although the
reason for this differential expression is unclear, it might involve a different mechanism of immune
regulation. In addition, we demonstrate that in the lamina propria of the colon of patients with UC,
IL-10 is strongly expressed. In conclusion, the presence of HLA-G on the surface of intestinal
epithelial cell in patients with UC lends support to the notion that this molecule may serve as a
regulator of mucosal immune responses to antigens of unde®ned origin. Thus, this different
pattern of HLA-G expression may help to differentiate between the immunopathogenesis of CD
and UC.
Introduction
Ulcerative Colitis (UC) and Crohn's disease (CD), the two main
forms of in¯ammatory bowel disease (IBD), are chronic and
spontaneously relapsing disorders, whose frequency is
increasing. Both disorders appear to be immunologically
mediated. There is compelling evidence that the deregulation
of the mucosal immune system is a major contributing factor to
the pathogenesis of IBD (1,2). Although their etiology is
unclear, the pathogenesis of these diseases represents the
outcome of three essential, interactive cofactors: (i) the host
susceptibility, (ii) the enteric micro¯ora and (iii) the mucosal
immunity (3). The mucosal immune system senses the local
microenvironment, being able to recognize and avoid reac-
tions to commensal ¯ora, whilst retaining its capacity to
respond to episodic challenge from pathogens (4).
Histologically, whereas UC is characterized by continuous
mucosal in¯ammation with crypt abscesses and ulcers that
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typically spread from the most caudal part of the rectum, CD is
associated with segmental and transmural in¯ammation,
®stulas, edema and granulomas. The nature of the immune
response and the cytokine pro®le are under genetic control,
and it determines the features of the in¯ammatory process in
IBD. Thus, CD is associated with the production and secretion
of type 1 helper T cell (Th) cytokines, such as IFN-g, tumor
necrosis factor-a and IL-12 (1,5). In UC, the pattern of cytokine
is less clear, with a modi®ed Th2 response associated with
IL-15 and IL-10 (1±6). Among the cytokines implicated in UC,
IL-10 plays a key role in the regulation of the mucosal
in¯ammation, promoting physiological activation, and pre-
venting the pathological in¯ammation characteristic of IBD (7).
HLA-G is a non-classical major histocompatibility complex
(HLA) class I molecule, which is highly expressed by human
cytotrophoblast cells that constitute the maternal±fetal inter-
face (8±10) and protect trophoblasts from being killed by
uterine NK cells. Therefore, cytotrophoblast cells are impli-
cated in immune tolerance (11). The distribution of HLA-G
is tissue-restricted, and shows limited polymorphism and
alternative transcription of spliced mRNAs that encode seven
different isoforms: four membrane-bound (G1±G4) and three
soluble proteins (G5±G7) (12,13). These HLA-G isoforms
inhibit NK cytolysis from polyclonal peripheral blood mono-
nuclear cells and cytotoxic T cell function during the primary
allogenic reaction (14). Several studies have also shown that
HLA-G expression allows tumor cells to escape from normal
immune responses and to proliferate (15,16). Recently,
soluble HLA-G found in biopsies and serum from patients
undergoing heart transplantation has been associated with a
better graft acceptance (17).
In view of currently available information on UC and CD,
characterized by alterations in the balance of pro-in¯amma-
tory and regulatory cytokines, and a deregulation of the
immune response, and considering the immunoregulatory role
of HLA-G, we analyze the expression of HLA-G in intestinal
biopsies of patients with CD and UC. In addition, we




Forty-three patients entered the study, including 24 patients
with UC and 19 patients with CD (the patients were followed at
the German Trias i Pujol Hospital of Badalona, Barcelona,
Spain and the Clinic Hospital of Granada, Spain). The
diagnosis of UC and CD was based on standard clinical,
radiological endoscopic and histologic criteria. The patholo-
gists graded the biopsies.
Immunohistochemistry
Samples ®xed in formalin and paraf®n-embedded were used
for immunohistochemistry. HLA-G and IL-10 were detected
using a monoclonal antibody 4H84 [kindly provided by S.
Fisher and M. McMaster (9)] that recognized all denaturated
HLA-G isoforms, and an anti-human IL-10 antibody (Santa
Cruz Biotechnology, Inc., Santa Cruz, CA), respectively. An
IgG2a isotypic mAb (Sigma) was used as negative control.
Immunohistochemical staining was performed using the
UltraTech HRP Streptavidin±Biotin Universal detection system
(Immunotech, France). After deparaf®nization and rehydra-
tion, sections were microwaved in 10 mM citrate buffer (pH 6.0)
for antigen retrieval. Sections were cooled in PBS, and the
endogenous peroxidase activity was quenched with 3%
hydrogen peroxide in distilled water. Sections were then
treated with the protein blocking agent, incubated sequentially
with the primary antibody, after with a biotinylated secondary
antibody, and with the streptavidin±peroxidase reagent. The
immunoreaction was visualized with chromogen working
solution AEC (Immunotech, France). Finally, the sections
was counterstain with hematoxylin. A positive control and a
negative control tissue were always considered. The immu-
noreactive score was determined by the sum of extension and
intensity in the samples. The intensity of staining was meas-
ured in two sections by two independent observers, and
scored as 0 for negative, 1 for weakly positive, 2 for
moderately positive and 3 for strongly positive. The extent of
positive immunoreactivity was estimated as 0 for negative, 1
for positive immunoreactivity for 25% of the cells, 2 for 50%, 3
for 75% and 4 for 100%. A section was considered positive
when over 30% of cells were stained.
Results
Samples of colon from 43 patients were examined and the
histological diagnosis for active diseases was based on the
degree of in®ltration of neutrophils in the intestinal lamina
propria, crypts and epithelium. The expression of HLA-G
antigens in these samples was analyzed. Our results provide
the ®rst evidence of HLA-G expression in UC patients (Fig. 1A,
C and E). Indeed, all patients with UC (n = 24) tested showed a
positive expression of HLA-G, as demonstrated by immuno-
histochemistry using monoclonal antibody 4H84, which
recognizes all denatured HLA-G isoforms. In contrast, HLA-
G expression was totally absent in CD patients (Fig. 1B).
Therefore, this study indicates the unexpected expression of
the HLA-G proteins in UC, but never in CD.
An isotype-matched negative staining control is shown in
Fig. 1(D). In addition, there was no evidence of HLA-G
expression in intestinal biopsies of control patients (n = 3)
(data not shown). HLA-G was highly expressed in all intestinal
tissues of UC, regardless of the intestinal location (ascending,
transverse, descending colon, or ileum), and of the medical
history and regimen of the patients. The expression of HLA-G
was restricted to the apical surface of intestinal epithelial cells
(IECs) in the epithelial layer in the intestinal mucosa (Fig. 1A)
and Lieberkun crypts (Fig. 1E). At higher magni®cation, this
intense apical staining can be observed (close-up view,
Fig. 1A). IECs from sections both actively in¯amed and
uninvolved areas of UC revealed similar patterns of staining.
No immunoreactivity was found in the other mucosal cell types
such as lymphocytes, macrophages, endothelial cells and
Peyer's patches, as shown in Fig. 1(E). The IECs have
extensive contact with T lymphocytes both within the epithe-
lium and in the underlying lamina propria. IECs are capable of
expressing HLA-G molecule in mucosal in¯ammation pro-
duced by ulcerative colitis with the associated production of
in¯ammatory cytokines.
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These results support the essential role of IECs in the
regulation of the mucosal immune response, an important role
of these cells in the pathology of UC. Moreover, our results
indicate a difference between CD and UC, and suggest that
increased HLA-G expression might just be a consequence of
the immune dysfunction characteristic of UC.
On the other hand, it is conceivable that HLA-G expression
in UC might re¯ect a down-regulation of the immune response
against in¯ammation, in addition to IL-10 production. Previous
studies in trophoblast and monocytes have demonstrated that
HLA-G is inducible by IL-10 (18,19). Then, we tested for the
presence of IL-10-producing cells in patients with UC and CD.
Immunohistochemistry for IL-10 was performed on formalin-
®xed tissues of patients with UC and CD, and the immuno-
reactivity was scored semiquantitatively. A strong IL-10
immunoreactivity was observed in the lamina propria cells in
all UC HLA-G-positive cases (Fig. 2A). This cytokine was
expressed mainly in in¯ammatory in®ltrates enriched in
macrophages, although T cells also seem to contribute to its
production. IL-10 might bind to a speci®c receptor on IECs
Fig. 1. (a) Immunohistochemistry of HLA-G expression in patients with UC. We observed a strong reactivity in the apical surface of IECs in the
epithelial layer in the intestinal mucosa (arrow). Magni®cation: 3200. (close-up view, 31000). (b) The absence of HLA-G expression in
CD mucosal epithelium. Magni®cation: 3200. (c) Expression of HLA-G in IECs in the epithelial layer in the intestinal mucosa in patients with
UC (arrow). Magni®cation: 3200. (d) An isotype-matched negative control IgG2a in patients with UC. Magni®cation: 3200. (e) HLA-G in
ulcerative colitis, strong positive signal in the ileal mucosal epithelium and crypt level. Peyer's patches showing negative signal (star).
Magni®cation: 3200.
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and modulate the contribution of these cells to the in¯amma-
tory and immune response in the digestive tract.
Discussion
We demonstrate for the ®rst time that in the in¯ammed mucosa
of UC patients, the HLA-G molecule is strongly expressed on
IECs, suggesting a protective role for these cells in such
pathology. Indeed, it had been described that in addition to
their important function in absorption and transport of nutri-
ents, IECs play an important role in innnate and adaptive
immunity (20). In UC, the speci®c expression on the apical
surface of IECs of HLA-G, a molecule involved in immune
tolerance (21), would be essential in maintainence of tolerance
to food antigens and gut micro¯ora. This tolerance may be
associated with this selective HLA-G expression in IECs. Also,
HLA-G has a signi®cant importance in the regulation of the
response of lymphocyte to damaged IECs.
However, such expression is likely to be insuf®cient to
protect the intestine from the in¯ammation induced by foreign
antigens that are unsuccessfully eliminated from the mucosa,
and from an acute immune response. In this sense, after
aggression is stopped, HLA-G may participate in the sup-
pression of the activity of pro-in¯ammatory cytokines, and in
the return of the immune response to a basal state.
Since HLA-G is more widely expressed than originally
believed, including on epithelial surfaces, and because this
molecule suppresses NK lysis (22), mechanisms of NK
inhibition may be operating in UC. Thus, HLA-G expression
might protect IECs from NK-mediated lysis. Moreover, a
previous report demonstrated that HLA-G regulates the Th1/
Th2 cytokine balance in a way that may shift towards relative
Th2 dominance (23). This is compatible with a possible role for
Th2-type responses in UC.
IL-10 is a regulatory cytokine that plays a crucial role in the
balance of the mucosal immune system, preventing the acute
in¯ammation that characterizes IBD (24,25). IL-10 is important
for the intestinal immune response and tolerance to
components of intestinal ¯ora. In its absence, luminal antigens
stimulate a Th1-dependent response that leads to an intestinal
in¯ammation. Changes in the microenvironment may create a
relative IL-10 de®cit in the in¯amed intestinal mucosa of CD
patients. Alterations in the production of many cytokines have
been described in patients with active IBD. We found that IL-
10 was expressed in all patients with UC, and in all of the HLA-
G positive cases, suggesting that IL-10 up-modulated HLA-G
expression in this in¯ammatory disease, and that this cytokine
may regulate the role of IECs in the in¯ammatory and immune
response. The presence of receptor for IL-10 on IECs (26)
makes this an attractive hypothesis. The intestinal mucosa is in
a constant state of controlled in¯ammation, although the
mechanisms implicated in this homeostasis are poorly under-
stood.
HLA-G is a non-classical MHC molecule whose expression
interferes with the function of immunocompetent NK and T
cells, leading to immunological tolerance. HLA-G may thus
recalibrate the delicate balance between tolerance and
responsiveness in the intestinal mucosa. In addition to IL-10
production, HLA-G expression might be one way to down-
regulate the immune response in UC.
The differential expression of HLA-G in UC and CD may be
linked to differences in the pathogenesis of these two
diseases. Moreover, it may be relevant to discern between
these two in¯ammatory diseases for diagnostic purposes.
Although the etiologic agents responsible for IBD have not yet
been elucidated, our results may help to understand the
in¯ammatory process in IBD. An improved knowledge of the
mechanisms implicated in the expression and secretion of
HLA-G during IBD will allow future therapeutic approaches
aimed at preventing tissue damage.
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